Rontalizumab

Edit links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Vanished user 0x8cSXE0x6 (talk | contribs) at 18:35, 4 June 2016. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Rontalizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetIFN-α
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6486H9990N1722O2026S44
Molar mass145.9 kg/mol g·mol−1
 ☒NcheckY (what is this?)  (verify)

Rontalizumab is a humanized monoclonal antibody[1] being developed by Genentech.[2] As of November 2009, it is being investigated in a clinical trial or the treatment of systemic lupus erythematosus.[3]

References

  1. ^ WHO Drug Information
  2. ^ Genentech: Rontalizumab (rhuMAb IFN alpha)
  3. ^ Clinical trial number NCT00962832 for "A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus (ROSE)" at ClinicalTrials.gov


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Rontalizumab&oldid=723708697"